Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Nov

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Welcome and Introduction to Vi3C

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure

Could a Liquid Biopsy Lead to Earlier Diagnoses for Numerous Cancer Types

Does Regular Opioid Use Increase Risks for Certain Cancers

More Patients With Cancer Are Using Crowdfunding to Pay for Care and Coming up Short

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma